A recent genomic analysis of a large G12C mutant lung cancer cohort treated with G12C inhibitors revealed that co-occurring mutations of KEAP1, SMARC4 and CDKN2A were independent negative predictive factors of inhibitor efficacy while mutations in the DDR genes were positive predictive ones [45]. The gene discussed is KEAP1; the disease is lung cancer.